Breaks Categories: News

MondayApr 10, 2017 10:01 am

HempNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Submits International Patent Applications for IGC-501

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that it has filed patent applications for IGC-501 in Canada, Israel and Europe in support of its ongoing cannabis-based combination therapy development initiatives. “We continue to strengthen our IP position in cannabis-based combination therapies and have progressed to include global patent filings,” Ram Mukunda, CEO of IGC, stated in the news release. “IGC is committed to addressing high potential international markets as a first mover in this emerging segment of cannabis-based combination therapy pharmaceuticals.” IGC-501 is being developed…

Continue Reading

ThursdayApr 06, 2017 12:26 pm

HempNewsBreaks – Player’s Network, Inc. (PNTV) CEO Releases Letter to Shareholders

Diversified holding company Player's Network, Inc. (OTCQB: PNTV) today released a shareholder letter from CEO Mark Bradley discussing several of the company’s recent achievements, as well as its corporate outlook for the remainder of 2017. Among PNTV’s first quarter highlights, the company completed an uplisting to the OTCQB® Venture Market and paid down the majority of its outstanding debt. Through its Green Leaf Farms Holdings ("GLFH") subsidiary, of which PNTV owns an 86 percent stake, the company also received a Certificate of Occupancy from the City of North Las Vegas for the first phase of a planned 27,000-square-foot facility that…

Continue Reading

ThursdayApr 06, 2017 11:03 am

HempNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Broadens its Horizon with Pipeline of Cannabis-Based Therapies

Since its inception in 2005, India Globalization Capital (NYSE: IGC) has transitioned from a mining company to a developer of cannabis-based therapies. The company is unique in that it uses cannabis-based extracts in combination with other medications to reduce side effects and increase bioavailability and absorption. “The company now has a pipeline of patent pending cannabinoid-based drugs targeting large market maladies, which includes therapeutics for neuropathic pain, human and animal seizures, refractory epilepsy and eating disorders. Several of these therapeutic drugs are scheduled for pre-clinical trials this year. The company is transitioning fast from building research teams and developing a…

Continue Reading

WednesdayApr 05, 2017 11:14 am

HempNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Attending ‘Invest 2017’ Exhibition

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced plans to attend the ‘Invest 2017’ exhibition, which is set to take place on April 7-8 in Stuttgart, Germany. Noted as the leading trade fair and congress for finance and investment in Germany, Invest 2017 is expected to provide CIIX with an opportunity to introduce its media and nutritional hemp companies to a crowd of German investors. “I am delighted that CIIX is invited to attend Invest 2017 as an exhibitor,” Warren Wang, founder and CEO of CIIX, stated in this morning’s news release. “This exhibition provides CIIX a valuable…

Continue Reading

WednesdayApr 05, 2017 10:11 am

HempNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Announces Sale of Brilliant Hallmark Stake

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced the sale of its investment interest in Brilliant Hallmark for a consideration of four million shares of IGC. The shares, which were previously issued to Brilliant Hallmark on August 4, 2016, will be returned and retired, while the Brilliant Hallmark investment will be removed from the company's balance sheet with an associated reduction of roughly $1.88 million. Per this morning’s update, IGC does not expect to record a gain or loss from this transaction. “This strategic move is…

Continue Reading

TuesdayApr 04, 2017 3:50 pm

HempNewsBreaks – InMed Pharmaceuticals, Inc. (IMLFF) Takes Aim at Rare Skin Diseases with INM-750

Epidermolysis bullosa (EBS) is a group of rare inherited skin diseases that unfortunately have no currently approved or known cure or treatment. InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) has developed INM-750 as the first therapy to specifically treat EBS. “Earlier this month, InMed filed an international Patent Cooperation Treaty application for intellectual and commercial protection of INM-750 and a cannabinoid-based therapy for EBS. This marks a significant milestone for the company, serving as validation for its efforts to develop new therapies based on cannabinoids and its unique approach to drug development. The company is using a proprietary bioinformatics assessment tool to…

Continue Reading

ThursdayMar 30, 2017 11:13 am

HempNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Invests in Breakwater MB, LLC

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced its investment in Breakwater MB, LLC, a cannabis-focused investment and consulting company formed by CIIX board member and former CFO Paul Dickman. CIIX’s initial investment into Breakwater MB will total $250,000, with the company maintaining an option to make additional investments at its own election. Per the news release, Breakwater MB intends to use the invested capital primarily to cover the costs of becoming a publicly traded company. CIIX management expects that this strategy will provide significant investment appreciate and opportunity for liquidity. “With the gradual opening up of the…

Continue Reading

ThursdayMar 23, 2017 9:38 am

HempNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) CEO Featured in Audio Interview with HempWire

Multifaceted financial news and publishing company HempWire this morning announced the online availability of a new audio interview with India Globalization Capital, Inc. (NYSE MKT: IGC) CEO Ram Mukunda. In the interview, Mukunda discusses IGC’s operations and targeted market, as well as leading formulations currently in the company’s development pipeline. “This is a very exciting time for us, an exciting opportunity,” Mukunda noted in the interview. “We believe that we have first-mover advantage in combination therapy, as very few companies are actually working on cannabis-based pharmaceuticals and within that space we believe that we are the only ones working on…

Continue Reading

WednesdayMar 22, 2017 2:38 pm

HempNewsBreaks – InMed Pharmaceuticals (IMLFF) Featured in Forbes Article Discussing Unique Cannabinoid Manufacturing System and Database

InMed Pharmaceuticals (OTCQB: IMLFF) was recently featured in a Forbes article highlighting the company's cannabinoid manufacturing system and database, which is used to map different compounds of cannabinoids to the various diseases they are able to treat. According to the article, InMed’s database appeals to other biotech companies who are now willing to purchase the information. Using its database, InMed has been able to identify two new cannabinoid therapies. Additionally, the company has created a method of biosynthesis for cannabinoids that is comparable to the system used to create synthetic insulin for diabetic patients. The company begins with the cannabinoid…

Continue Reading

TuesdayMar 21, 2017 9:58 am

HempNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Files Provisional Patent for Treatment of Eating Disorders Using Cannabis Extracts

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced its filing of a provisional patent for the treatment of multiple types of eating disorders by a method and combination of cannabis extracts and other compounds. Should this filing result in the issuance of a patent, IGC intends to develop its IGC-506 candidate for both human and veterinary use. “The development of cannabis-based combination therapies represents a large, unique opportunity, and we believe we are the first mover in this emerging specialty-pharmaceutical sector,” Ram Mukunda, chief executive officer…

Continue Reading